Ovarian cancer is a highly metastatic and lethal disease, making it imperative to find treatments that target latestage malignant tumors. The packaging RNA (pRNA) of bacteriophage phi29 DNA-packaging motor has been reported to function as a highly versatile vehicle to carry small interference RNA (siRNA) for silencing of survivin. In this article, we explore the potential of pRNA as a vehicle to carry siRNA specifically targeted to metallothioneinIIa (MT-IIA) messenger RNA (mRNA), and compare it to survivin targeting pRNA. These two anti-apoptotic cell survival factors promote tumor cell viability, and are overexpressed in recurrent tumors. We find that pRNA chimeras targeting MT-IIA are processed into double-stranded siRNA by dicer, are localized within the GW/P-bodies, and are more potent than siRNA alone in silencing MT-IIA expression. Moreover, knockdown of both survivin and MT-IIA expression simultaneously results in more potent effects on cell proliferation in the aggressive ovarian tumor cell lines than either alone, suggesting that therapeutic approaches that target multiple genes are essential for molecular therapy. The folate receptor-targeted delivery of siRNA by the folate-pRNA dimer emphasizes the cancer cell-specific aspect of this system. The pRNA system, which has the capability to assemble into multivalent nanoparticles, has immense promise as a highly potent therapeutic agent.
IntroductIon
Ovarian cancer is a highly metastatic and lethal disease with an estimated 13,850 deaths annually and 21,880 new cases diagnosed in 2010. It has the highest mortality of all cancers of the female reproductive system, although it is treatable when detected early. Unfortunately, most diagnoses occur at advanced stages of disease, when the cancer has usually metastasized, spread beyond the ovary, and is difficult to treat.
Survivin has a pivotal role in tumor cell survival (reviewed in Altieri 1 ) and is differentially expressed in ovarian tumor cells as compared to most normal tissues. [2] [3] [4] Survivin expression correlates with proliferative index, clinical stage, histological grade, clinical outcome, and survival rate in epithelial ovarian and endometrial carcinomas. [2] [3] [4] Preclinical studies have demonstrated that downregulation of survivin expression or function reduced tumor growth potential and increased tumor cell apoptotic rate in various human tumor models (reviewed in Pennati et al. 5 ). These factors make survivin an attractive target for gene therapy.
Metallothionein (MT) family of metal-binding proteins confers protection against apoptosis 6 and plays an important role in cell proliferation; 7 both processes are important in carcinogenesis. The increased expression of MT in malignant as opposed to benign ovarian surface epithelial tumors and also with increasing histological grade tumors 8, 9 suggests a role for MT in tumorigenesis. To date, there are seven MT-I functional isoforms, but only one MT-II functional isoform (named MT-IIA) characterized. The survival of mice lacking functional MT-I and MT-IIA genes 10 indicates that these proteins are not crucial factors for normal cell survival. 10 However, silencing MT-IIA expression induces apoptosis in cancer cells, [11] [12] [13] without augmenting the expression of MT-I isoforms, making MT-IIA a candidate for therapeutic intervention.
There has been an increased interest in RNA interference (RNAi) as a therapeutic approach for treatment of cancer. There is accumulating evidence that delivery of small interference RNA (siRNA) (targeting anti-apoptotic genes) as dicer-substrate siRNA (d-siRNA-27 bp) can be up to a 100-fold more potent than the traditional 21-mer siRNA. [14] [15] [16] Moreover, by coupling synthetic d-siRNA with a cancer cell-specific ligand or a RNA aptamer 17, 18 targeted toward a cancer-specific receptor, one can potentially target delivery of d-siRNA only to cancer cells. This mode of d-siRNA delivery is gaining importance because the preformed d-siRNA is extremely potent at gene silencing, is short lived, 19, 20 and is rapidly cleared by the system, eliminating long-term effects. Another approach to deliver siRNA into cells for gene therapy is with packaging RNA (pRNA) of bacteriophage phi29. [21] [22] [23] [24] pRNA is a component of the bacteriophage phi29 DNApackaging motor. 25, 26 pRNA (Figure 1a ) can form dimers, trimers, and hexamers. 24, 27, 28 Each pRNA contains two functional domains. The central domain of pRNA contains two interlocking left hand and right hand loops that can be engineered to form stable intermolecular loop-loop interactions 27 ( Figure 1a) . The DNA-packaging domain is located at the 5′/3′ paired ends. 29 The two domains fold separately, and replacement of the packaging domain with siRNA does not affect pRNA structure, folding, or intermolecular interactions. 29, 30 The resultant pRNA/siRNA chimera is useful for gene therapy.
We have previously shown that the pRNA/si(Surv) chimera can be used for the delivery of siRNA targeting survivin into breast, prostate, and nasopharyngeal carcinoma cells. [21] [22] [23] In this report, we explore the potential use of pRNA to carry siRNA specific for MT-IIA, and compare its efficacy to induce cell death with that of a survivin targeting pRNA in ovarian cancer cells. We show that the pRNA/siRNA can be processed by dicer, and can downregulate MT-IIA and survivin messenger RNA (mRNA) levels when introduced into cells, resulting in decreased cell proliferation. Moreover, the pRNA/si(MT2A) is more efficient than the synthetic 21-mer siRNA alone, in silencing MT-IIA expression. Finally, we show that (Figure 1a) . To construct the pRNA/ siRNA chimeras targeting either MT-IIA or survivin, the 5′/3′ helical DNA-packaging domain was replaced by the respective siRNA (Figure 1a) , or by a random sequence as a control. The transcribed RNA was analyzed on a denaturing gel to verify the correct size of the pRNA/siRNA chimera ( Figure 1b the prnA/sirnA construct is processed by dicer Next, to confirm that the Ba′pRNA/siRNA chimeras could be processed into siRNA by dicer in vitro, chimeric pRNA/siRNA were treated with purified recombinant dicer, which processes long double-stranded RNA into siRNAs. We had previously shown by 5′ end 32 P end-labeling that a 22-base siRNA can be generated with high efficiency by pRNA/siRNA chimera digestion with dicer. 21 Purified Ba′pRNA/siRNA chimeras were mixed with dicer, and the digested product was then analyzed on denaturing polyacrylamide gel electrophoresis (PAGE)/urea gels. As shown in Figure 1d , digestion of the pRNA/siRNA chimeras by dicer resulted in production of 17-22-base siRNA (Figure 1d) , which are absent in the nondicer containing lanes. This result confirms that similar to d-siRNA, the chimeric pRNA/siRNA is cleaved by dicer, and the double-stranded siRNA located at the 5′/3′ ends, are released. Moreover, when examined under a microscope, the majority of Ba′pRNA/si(MT2A)-and Ba′pRNA/si(Surv)-transfected cells were rounded with dark condensed nuclei, and detached from the cell culture plate (Figure 3b) . However, we noticed that the highly metastatic SKOV-3 cells consistently showed higher levels of cell survival compared to OVCA 432 and OVCA 433 cells (Figure 3a) , when transfected with Ba′pRNA/si(MT2A). We examined the transfection efficiency by co-transfecting each pRNA/siRNAs along with pGFP, and counting the number of GFP-positive cells, and by transfecting Cy3-labeled pRNA/si(CONT2), into the three cell lines. We found that there was no significant difference among the cell lines, and their transfection efficiencies were comparable (70-90% for pRNA/siRNA). Because expression of both MT-IIA and survivin give cells a survival advantage, we examined the levels of survivin mRNA within the Ba′pRNA/si(MT2-1)-and Ba′pRNA/si(MT2-2)-transfected cells. Whereas transfection of Ba′pRNA/si(MT2A) led to decrease in survivin expression in OVCA 432 and OVCA 433 cells, such a decrease was not observed in SKOV-3 cells (Figure 3c) . Moreover, when we examined MT-IIA expression in Ba′pRNA/si(Surv)-transfected SKOV-3 cells, an increase in MT-IIA expression (Figure 3d) was found, implying a compensatory effect of survivin silencing on MT-IIA expression. Transfection of any of the three Ba′pRNA/siRNAs had no effect on the expression levels of Bcl-2 mRNA, another anti-apoptotic gene examined, indicating that this phenomenon was not a nonspecific effect (results not shown). Finally, SKOV-3 cells were co-transfected with either Ba′pRNA/si(MT2-1) or Ba′pRNA/si(MT2-2), and Ba′pRNA/si(Surv), to determine whether the combination would be more potent than either alone. Indeed, SKOV-3 cells silenced for MT-IIA and survivin showed a ~70% decrease in cell survival (Figure 3e) . It has been shown that T7 RNA polymerase-transcribed siRNA with the 5′ end phosphate group intact (pppG) can elicit interferon (IFN)-α and IFN-β expression leading to nonspecific inhibitory effects on cells. 34 Hence, we examined OVCA 433 cells transfected with the Ba′pRNA/siRNA for IFN-α and IFN-β expression, and found it to be negligible (Supplementary Figure S1) . the inhibitory function of the prnA/sirnA is more potent than the 21-base synthetic double-stranded sirnA Recent observations regarding the more potent interfering function of d-siRNA 18 indicate that the chimera pRNA/siRNA should also be more effective than the 21-base siRNA in its inhibitory function. To compare the relative potencies of 21-mer siRNA and pRNA/siRNA, we transfected OVCA 433 cells with both Ba′pRNA/ siRNA and the 21-mer siRNA targeted to MT-IIA. Compared to pRNA/siRNA-transfected cells, we found that higher molar amounts of siRNA were required to obtain equivalent MT-IIA gene silencing. That is, although 2 nmol/l of Ba′pRNA/si(MT2-1) and Ba′pRNA/si(MT2-2) were sufficient to induce 40-50% decrease in MT-IIA levels (Figure 2c) , 33 nmol/l of the 21-mer siRNA was required to knockdown the equivalent amount (Figure 4a) . This effect was reflected in the cell proliferation. Whereas a significant decrease in cell proliferation was obtained with 2 and 8 nmol/l of Ba′pRNA/si(MT2-1) and Ba′pRNA/si(MT2-2) (Figure 4b) , equivalent amounts of siMT2-1 and siMT2-2 did not have any effect on cell survival. A maximum of 20% decrease in cell proliferation was obtained with 33-200 nmol/l siRNA, indicating that the interfering effect is not as potent in 21-mer siRNAtransfected cells (Figure 4c) . Similar effects on cell viability have been reported by other researchers 13 with the 21-mer siRNA in breast cancer cells. This provides evidence that our pRNA chimera system is more efficient than a 21-mer siRNA-based system, with greater therapeutic value. the prnA/sirnA chimera are present within the GW/P bodies The mammalian GW182 protein, a major component of P-bodies, 35 has been found to colocalize and coimmunoprecipitate with Argonaute (Ago) proteins. 35, 36 It has been shown that the GW182 protein interaction with Ago2 and their colocalization at multivesicular bodies are important in microRNA-and siRNAmediated RNAi. 37, 38 Although the exact role of GW182 is not known, it has been proposed that RISC (RNA-induced silencing complex) plays a role in targeting mRNAs to GW-rich bodies 38 where the mRNA is either degraded or translationally repressed. We thus determined whether the pRNA/siRNA chimeras localize within the GW/P-body complex. The pRNA/si(CONT2) chimera was labeled with Cy3 (Figure 5a ) so that it could be tracked to investigate its subcellular localization in OVCA 433 cells. As a control, the FITC-siRNA (Invitrogen, Carlsbad, CA) was employed. Live image microscopy was performed. The Cy3 signal of pRNA/si(CONT2) was localized within discrete speckles within the cytoplasm (Figure 5b, 1-3 ), compared to a predominant nuclear and a uniform cytoplasmic appearance of the FITCsiRNA signal (Figure 5b, 4-6 ). However, it should be noted that some speckles were also observed in the FITC-siRNA-transfected cells (Supplementary Figure S2) . Moreover, the Cy3 signal persisted for 6 days post-transfection, compared to the siRNA signal which faded within 72 hours (Supplementary Figure S2) . The signal pattern obtained with Cy3-pRNA/si(CONT2) was similar to that obtained with siRNA-and miRNA-processing proteins Ago2 and GW182. 35 ,39,40 Therefore, we immunostained OVCA433 cells expressing Cy3-pRNA/si(CONT2) with mouse anti-GW182 antibody to determine whether the Cy3 signal was localized within the GW-bodies. We found that some of the Cy3-pRNA/ si(CONT2) signal colocalized with the GW182 positive signal (Figure 5c ), indicating that the pRNA/siRNA are present at sites involved in mRNA degradation.
targeted delivery of folate-tagged prnA into ovarian cancer cells
The ability of pRNA nanoparticle 30 to form dimers makes it extremely useful for targeted delivery of siRNA into cancer cells. That is, the Ba′pRNA/siRNA form dimers with folate-Ab′pRNA for delivery into folate receptor expressing ovarian cancer cells. A number of researchers have found that folate receptor-α is highly expressed in ovarian carcinomas compared to normal tissue, with nearly 89% ovarian carcinomas staining positive for folate receptor. 41 We examined ovarian cancer cell lines for folate receptor-α expression by qRT-PCR and found highest levels in SKOV-3 cells (Figure 6a) . Next, we made the folate-Ab′pRNA (as outlined in Materials and Methods) and confirmed that the folate moiety does not interfere with the heterodimerization of Ab′pRNA with Ba′pRNA/siRNA chimeras. The Ba′pRNA/siRNA chimeras were mixed with folate-Ab′pRNA and analyzed on a nondenaturing gel. The change in mobility of the bands indicates that the folatepRNA (Figure 6b, lane 4, 7, 8, 13, 16, 17) can efficiently form dimers with Ba′pRNA/siRNA chimeras (Figure 6b, lanes 7, 8, 16 , and 17). The positive control, Ab′pRNA-Ba′pRNA (Figure 6b, lanes 9,  18) runs as a dimer and the individual pRNA/siRNA run as monomers (lanes 1-3, 5, 6, 10-12, 14, 15) . We determined the ability of folate-pRNA-Cy3-pRNA dimer to bind cells which express folate receptor-α by flow cytometry (Figure 6c ) and confocal image microscopy (Supplementary Figure S5) as described in Materials and Methods. As shown in Figure 6c , we found that ~15% of cells are bound by folate-pRNA-Cy3-pRNA dimer, whereas <1% of cells are bound by Cy3-pRNA, or NH 2 -pRNA-Cy3-pRNA dimer (negative controls). Moreover, we could compete the binding of folatepRNA-Cy3-pRNA dimer to cells with free folate (Figure 6c) . Finally, we treated SKOV-3 cells with folate-pRNA-pRNA/siRNA dimers. We obtained a statistically significant decrease in expression of MT-IIA and survivin on treatment with the respective RNA (Supplementary Figure S6) . Moreover, we found a statistically significant 20-45% decrease in cell survival on treatment with folatepRNA-Ba′pRNA/si(MT2-1), folate-pRNA-Ba′pRNA/si(MT2-2), and folate-pRNA-Ba′pRNA/si(Surv) (Figure 6d ) compared to control-treated cells. Treatment with control pRNA-Ba′-pRNA/ siRNA dimers without folate labeling, which cannot bind SKOV-3 cells, exhibited no effects on cell growth and survival, indicating that the folate-pRNA is required for the pRNA dimer chimera to enter cells. Lastly, we performed both cleavage site overlap RT-PCR and a modified 17 5′-RACE [rapid amplification of complementary DNA (cDNA) ends] PCR, and verified the presence of the specific cleavage product (Supplementary Figure S6) indicative of pRNA/ siRNA-mediated cleavage of MT-2A and survivin mRNA.
dIScuSSIon
The 117-nt RNA nanoparticle 30 derived from the phi29 DNApackaging RNA is ideally suited for delivery of siRNA directed toward multiple gene targets. 27, 28 It has the potential of being safe, noninfectious/nonpathogenic and resistant to degradation. We investigated the utility of the pRNA nanoparticle as a siMT-IIA fusion chimera to inhibit expression of MT-IIA, and induce decreased cell proliferation of pRNA/si(MT2A) chimera-transfected cells. We found that the pRNA/siRNA was processed by dicer (Figure 1, Supplementary Figure S7) , localized to GW182 containing speckles, and inhibited the expression of the target gene. Moreover, transfection of both pRNA/si(MT2A) and pRNA/ si(Surv) individually and together, decreased cell proliferation. We found similar results in breast and prostate cancer cells (data not shown). Thus, in addition to survivin, 22 targeting MT-IIA gene expression could be a second molecule in the arsenal for treating ovarian cancers, and this pRNA nanoparticle, is excellent for delivery of highly potent siRNA.
For the pRNA/siRNA to efficiently function in RNAi, it has to be correctly processed by dicer, 42, 43 and delivered to the GW-rich bodies. We have shown that both events occur and that the pRNA/ siRNA chimera is highly efficient in triggering RNAi. It has recently been described 16, 20 that RNAi by chemically synthesized d-siRNA duplexes in the 25-30 base length range are more potent than 21-mer siRNAs in the same location. The observed increased potency obtained using longer d-siRNAs in triggering RNAi is thought to result from providing dicer with a substrate instead of a product, which improves the rate or efficiency of entry of the d-siRNA into RISC as facilitated by dicer. 44 Alternatively, this could be due to the pRNA/siRNA-processed RISC-siRNA functioning as a multiple-turnover enzyme that recognizes and cleaves its target multiple times resulting in a more potent, longer-lasting effect. It should be noted that although 33 nmol/l siMT-IIA had similar gene silencing efficiency as 2 nmol/l pRNA/si(MT2A), the siRNA was less potent than the corresponding pRNA/siRNA at decreasing cell survival. Because negligible amounts of IFN-α and IFN-β were detected, this was not a toxicity issue. We reasoned that this could be a question of relative pRNA stability within cells, because the RNA expression studies and cell proliferation studies were performed at different time points. The siRNA might be more prone to degradation than pRNA/siRNA, and thus less effective in the long term. Alternatively, the GW/P bodies are believed to be sites of mRNA degradation as well as translational repression. 45 A working model for how RISC interacts with cytoplasmic mRNAs has been proposed 45 where siRNA-RISC first interacts with its target mRNA. If this interaction is stable, RISC remains bound leading to translational repression and the accumulation of the mRNA/RISC in GW/P-bodies, although the molecular details of that effect remain unclear. Moreover, if RISC contains a cleavagecompetent Ago protein, the mRNA is cleaved before, during, or after accumulation of the mRNA:RISC in GW/P-bodies. The stage at which endonuclease cleavage occurs would simply be a function of the relative rates of cleavage versus translation repression and GW/P-body accumulation. We found that the siRNA of pRNA/ siRNA was more stable within cells, and present within the GW/ P-bodies 6 days post-transfection (Supplementary Figure S2) . Because MT is an extremely small protein (~7 kDa) and MT-IIA isoform antibodies cross-react with MT-I, we could not analyze MT-IIA by western blot. However, we immunostained pRNA/ si(MT2A)-transfected cells for MT expression and found lower levels of staining intensity in pRNA/si(MT2A)-transfected cells compared to control cells (Supplementary Figure S3) . Moreover, we used cleavage site overlap RT-PCR to confirm mRNA cleavage of MT-2A and survivin in pRNA/si(MT2A)-and pRNA/si(Surv)-transfected cells (Supplementary Figure S4) .
Relatively subtle perturbations of anti-apoptotic protein expression, stability or binding to associated molecules can irreversibly impair cell viability. We observed that although the expression of survivin mRNA decreased by 20% on transfection of pRNA/si(Surv) in SKOV-3 and OVCA 433 cells, its effects on cell proliferation was >20%, depending on cell type. This could be due to the fact that survivin expression in SKOV-3 and OVCA 433 cells is three-to sixfold lower than that present in OVCA 432 cells. Once survivin expression fell below a threshold level, cell death was triggered. Hence, even a 20-30% decrease in survivin in SKOV-3 and OVCA 433 cells was sufficient to trigger cell death.
The ability of pRNA chimeras to form dimers makes them extremely useful for targeted delivery of siRNA into cancer cells. We showed that the pRNA/siRNA-folate-pRNA dimer can deliver siRNA to folate receptor-α expressing ovarian carcinoma cells. 21 However, only 15% of the folate-pRNA dimer bound to cells. Previous studies have indicated that pRNA forms dimers with high efficiency which are very stable in solutions. [46] [47] [48] The low binding efficiency to cells may reflect the degradation of pRNA in serum. To compensate for the low folate-pRNA dimer cell-binding activity, we have performed two rounds of treatment with folatepRNA-pRNA/siRNA dimers, and observed a significant decrease in cell survival in the presence of MT-IIA and survivin targeting pRNA/siRNA, indicating the high potential of this delivery system. We are working on making the pRNA resistant to degradation, a key step essential for transition to preclinical animal trials. As a consequence of our findings, we can envision future studies aimed at cancer cell-specific, folate-mediated uptake of siRNA targeting survivin and MT-IIA as a pRNA trimer. This strategy has the potential for targeting a single cell with multiple molecules, making pRNA nanoparticle-mediated delivery ideally suited to overcome the extraordinary heterogeneity of human cancer.
In summary, we have shown that: (i) pRNA/siRNA chimera can be efficiently processed by dicer and are localized within the GW/ P-bodies, (ii) pRNA/si(MT2A) is more efficient than siRNA alone in silencing MT-IIA expression, (iii) pRNA/si(MT2A) and pRNA/ si(Surv) can be used to specifically silence MT-IIA and survivin mRNA expression, respectively, leading to decreased cell proliferation, (iv) folate-mediated uptake of pRNA/si(MT2A) and pRNA/ si(Surv) can inhibit cell growth/survival, and (v) the combination of pRNA/siRNA targeted toward survivin and MT-IIA leads to more potent effects on cell proliferation. Thus, the pRNA/si(MT2A) chimera provides another robust subunit for construction of pRNAbased multivalent therapeutic vehicle against cancer cells.
MAterIAlS And MethodS
Cell culture. Ovarian cancer cell line SKOV-3, nasopharyngeal carcinoma KB cells (American Type Culture Collection, Manassas, VA), and the primary human Ovarian Cancer (OVCA 432 and OVCA 433) and the ovarian surface epithelial (HOSE 642) cell lines have been described previously 31, 32 and are routinely maintained in RPMI 1640 medium and supplemented with 10% fetal bovine serum. Cultures were incubated at 37 °C in a humidified 5% CO 2 atmosphere; 7,000 cells were seeded into each well of a 96-well culture plate (Nunc, Rochester, NY) for in vitro experiments.
Nomenclature, construction, and synthesis of RNA. The nomenclature of pRNA and the resulting chimeric pRNA subunits for the construction of siRNA nanoparticles have been reported. 23 Briefly, upper-case and lowercase letters are used to represent the right and left hand loops of the pRNA, respectively. Figure S1 . pRNA/siRNA do not induce high levels of interferon-α and β expression. Figure S2 . Cy3-Ba′pRNA/si(CONT2) is localized within discrete speckles at 6 days post-transfection. Figure S3 . Immunofluorescence staining for MT expression. Figure S4 . Cleavage site overlap RT-PCR to demonstrate decreased levels of MT-2A and survivin products in pRNA/si(MT2A) and pRNA/ si(Surv) transfected cells. Figure S5 . Binding and entry of folate-labeled folate-pRNA-Cy3-pRNA/siRNA dimer particle. Figure S6 . Silencing of targeted MT-IIA or survivin. Figure S7 . Dicer processing of pRNA/siRNA.
SuPPleMentArY MAterIAl

